Skip to main content
SpringerLink
Log in

AKI in Setting of Cancer

  • Chapter
  • First Online:
Acute Kidney Injury and Regenerative Medicine

  • 606 Accesses

Abstract

Though the link between cancer and renal disease has long been known, at present their relationship is emphasized more strongly than ever. Several trends in oncology, including longer survival times, better supportive care, and cancer diagnosis at older ages due to increased life expectancy, are driving an increase in the number of cancer patients developing acute kidney injury. In addition, recent improvements in cancer therapy, including stem cell therapies and newer molecular targeted drugs, have led to the emergence of new etiologies of kidney disease. Renal diseases in cancer patients are different from those in other patients, and they are becoming increasingly complex to manage. It is necessary for both nephrologists and oncologists to stay up to date on the diagnosis and management of cancer-concurrent kidney complications to provide optimal treatment. This chapter addresses the pathophysiology and treatment of various kidney complications in the context of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399–406.

    Article  PubMed  Google Scholar 

  2. Soares M, et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol. 2006;24(24):4003–10.

    Article  PubMed  Google Scholar 

  3. Salahudeen AK, et al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347–54.

    Article  PubMed  Google Scholar 

  4. Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis. 2014;21(1):7–17.

    Article  PubMed  Google Scholar 

  5. Coppell JA, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.

    Article  PubMed  Google Scholar 

  6. Parikh CR, Coca SG. Acute renal failure in hematopoietic cell transplantation. Kidney Int. 2006;69(3):430–5.

    Article  CAS  PubMed  Google Scholar 

  7. Richardson PG, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92.

    Article  CAS  PubMed  Google Scholar 

  9. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986;137(5):1735–42.

    CAS  PubMed  Google Scholar 

  10. Hutchison CA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dimopoulos MA, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91(5):499–502.

    Article  CAS  PubMed  Google Scholar 

  12. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.

    Article  PubMed  Google Scholar 

  13. Cairo MS, Coiffier B, Reiter A, Younes A, Panel TE. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.

    Article  CAS  PubMed  Google Scholar 

  14. Törnroth T, Heiro M, Marcussen N, Franssila K. Lymphomas diagnosed by percutaneous kidney biopsy. Am J Kidney Dis. 2003;42(5):960–71.

    Article  PubMed  Google Scholar 

  15. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008;23(10):1761–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lesesne JB, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989;7(6):781–9.

    Article  CAS  PubMed  Google Scholar 

  17. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011;118(6):1452–62.

    Article  CAS  PubMed  Google Scholar 

  18. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005;16(1):151–61.

    Article  PubMed  Google Scholar 

  19. Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora’s box. Bone Marrow Transplant. 2017;52(10):1355–60.

    Article  CAS  PubMed  Google Scholar 

  20. Ramsey LB, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52–61.

    Article  CAS  PubMed  Google Scholar 

  21. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011;68(5):1207–13.

    Article  PubMed  Google Scholar 

  22. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18(6):1117.

    Article  CAS  PubMed  Google Scholar 

  23. Li Y, et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2014;16(3):177–85.

    Article  CAS  Google Scholar 

  24. Feldman DR, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(9):1432–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Azad NS, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26(22):3709–14.

    Article  CAS  PubMed  Google Scholar 

  26. Humphreys BD, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100(12):2664–70.

    Article  PubMed  Google Scholar 

  27. Fung MC, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85(9):2023–32.

    Article  CAS  PubMed  Google Scholar 

  28. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713–21.

    Article  CAS  PubMed  Google Scholar 

  29. Cortazar FB, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Beck LH, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wang J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Tomas NM, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–87.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Hoxha E, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520–31.

    Article  CAS  PubMed  Google Scholar 

  34. Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616–22.

    Article  CAS  PubMed  Google Scholar 

  35. Beauvais P, Vaudour G, Boccon Gibod L, Levy M. Membranous nephropathy associated with ovarian tumour in a young girl: recovery after removal. Eur J Pediatr. 1989;148(7):624–5.

    Article  CAS  PubMed  Google Scholar 

  36. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2003;18(2):245–8.

    Article  CAS  PubMed  Google Scholar 

  37. Audard V, et al. Minimal change nephrotic syndrome and classical Hodgkin’s lymphoma: report of 21 cases and review of the literature. Kidney Int. 2006;69(12):2251–60.

    Article  CAS  PubMed  Google Scholar 

  38. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–8.

    Article  PubMed  Google Scholar 

  39. Janus N, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Yuichiro Kitai, Takeshi Matsubara & Motoko Yanagita

Authors
  1. Yuichiro Kitai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Motoko Yanagita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Motoko Yanagita .

Editor information

Editors and Affiliations

  1. Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan

    Yoshio Terada

  2. Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan

    Takashi Wada

  3. Department of Acute Medicine, The University of Tokyo, Tokyo, Japan

    Kent Doi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kitai, Y., Matsubara, T., Yanagita, M. (2020). AKI in Setting of Cancer. In: Terada, Y., Wada, T., Doi, K. (eds) Acute Kidney Injury and Regenerative Medicine . Springer, Singapore. https://doi.org/10.1007/978-981-15-1108-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-1108-0_9

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-1107-3

  • Online ISBN: 978-981-15-1108-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation